JAMA Network summarizes VESALIUS-CV results suggesting evolocumab plus statin reduces first major cardiovascular events in patients with diabetes without known significant atherosclerosis, reinforcing earlier preventive lipid-lowering strategies.
Evolocumab for Heart Protection in People With Diabetes
intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event
without known significant atherosclerosis
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare